Neurology & Psychiatry · LP-154
Fluoxetine Capsules
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-154Neurology & Psychiatry
- Generic identity
- FluoxetineCapsule
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-154
- Generic ingredient
- Fluoxetine
- Dosage form
- Capsule
- Proposed strength
- 20 mg
- Proposed pack
- Blister 10 x 10 capsules
- Portfolio category
- Neurology & Psychiatry
About Fluoxetine
Fluoxetine is a selective serotonin reuptake inhibitor used in the treatment of defined mental-health conditions. It affects serotonin signalling and is distinct from sedatives or immediate symptom-relief medicines. Its clinical role depends on diagnosis, age and individual benefit-risk assessment. A capsule entry provides ingredient and dosage-form information; it does not establish that all uses or age groups described in a foreign reference are locally authorized.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
Assessment can consider depressive illness, obsessive-compulsive disorder or other specifically supported indications. A treatment plan includes follow-up of symptoms, functioning, tolerability and the possibility of bipolar disorder. Benefit may develop over time, and apparent early improvement or deterioration should be discussed with the treating professional. Fluoxetine remains in the body for a prolonged period, making medication changes and interaction review relevant beyond the day treatment stops.
Important safety considerations
Nausea, sleep disturbance, headache and sexual adverse effects can occur. Important risks include serotonin syndrome, low sodium, bleeding with certain interacting medicines and activation of mania. Suicidal thoughts or worsening agitation require prompt support, particularly when treatment begins or changes. Monoamine oxidase inhibitors and other serotonergic medicines require careful assessment. Stopping, switching or combining antidepressants should be planned with the prescriber rather than guided by this catalogue.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
The listed form is an oral capsule. Do not assume that it is suitable for opening, dispersing or administration through a feeding tube. Capsule shell materials, excipients and any alternative presentation require confirmation from the specific product information.
Keep the medicine in the labelled original pack with its leaflet. Check the expiry date and pack integrity before dispensing. The authorized label must determine storage temperature, protection from moisture or light, and disposal; no shelf life or in-use period can be established from a catalogue entry.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
Review diagnosis, suicide risk, bipolar history, interacting medicines and follow-up arrangements. The exact capsule and locally approved patient information must guide prescribing and dispensing.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Fluoxetine
- Dosage form / presentation
- Capsule
- Catalogue strength
- 20 mg
- Catalogue pack
- Blister 10 x 10 capsules
- Portfolio category
- Neurology & Psychiatry
Layer 02
Unresolved product-specific fields
- The 20 mg capsule entry does not establish immediate- versus delayed-release character, capsule-opening suitability, excipients or an alternative formulation.
- Approved indication, patient eligibility and dosing are not established by this portfolio record.
- Registration, manufacturing/site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- MedlinePlus: Fluoxetinegovernment-hosted medicine monograph
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Controlled product master/specification confirming exact active chemical form, dosage form, strength variant and pack mapping.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet/IFU, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-154, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-154.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.